COLUMBUS, Ohio – An important gene that normally protects the body against cancer can itself cause a variety of cancers depending on the specific mutation that damages it, according to a new study by investigators at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James).
The study examined mutations in a gene called PTEN. People who inherit a mutated copy of this gene have Cowden syndrome, a condition that carries a high risk of cancer in a number of organs, including the breast, thyroid and ovary. In addition, PTEN is frequently mutated in normal body cells leading to prostate, lung and pancreatic cancers.
Why people with Cowden syndrome develop different cancers, or cancers that are more severe in some than in others, is unknown, though the cause is often attributed to the natural genetic differences that exist between individuals.
This animal study, however, linked specific mutations in the gene to distinct kinds of cancer in organs targeted by the syndrome.
“We showed that the mutations themselves play a critical role in driving the cancers that occur in certain organs in people with Cowden syndrome,” says principal investigator Gustavo Leone, associate professor of molecular virology, immunology and medical genetics at the OSUCCC-James.
“Together, our findings demonstrate that specific inherited PTEN mutations have a strong influence in the variable predisposition to cancer of patients with Cowden syndrome.”
The findings, published in the March 16 issue of the Proceedings of the National Academy of Sciences of the United States of America, suggest that testing for specific PTEN mutations might predict the kind and severity of cancer that will develop in people with the syndrome.
Furthermore, because PTEN is the second most commonly mutated gene in human cancer overall, the same mutations might predict severity in sporadic tumors, as well.
“Mutations in this gene also play a role in developmental disabilities and perhaps in autism, so this mouse model might be useful for studies in those conditions, as well,” says co-principal investigator Michael Ostrowski, professor and chair of molecular and cellular biochemistry at Ohio State.
For this study, Leone, Ostrowski and their colleagues developed three strains of genetically identical mice, each of which had one of three specific PTEN mutations found in people with Cowden syndrome. This left each strain with a different version of the PTEN protein. The study showed that each version functioned in a different way, and each influenced cancer development to a different degree.
Mutation 1 disabled the protein altogether and often caused cancer in the animals, while mutation 2 produced a protein that was more active than the normal PTEN protein, and sometimes caused cancer. Mutation 3 altered the protein in ways that should have made it more cancer-causing but also made it more fragile, so less of the protein was present to cause problems. This mutation sometimes didn’t cause cancer at all.
Using a database of more than 400 patients with Cowden syndrome, the researchers found that patients with these same mutations have cancer in the corresponding organs as the mice. The mice also showed equivalent gender differences in tumor development, with females developing more thyroid tumors, and males developing more adrenal gland and stomach tumors.
The researchers are now investigating why patients may experience differences in cancer severity even when they have the same mutation.
Funding from the National Cancer Institute, the American Cancer Society, the Susan Komen Foundation, the Evelyn Simmers Foundation, and the U.S. Department of Defense supported this research.
Leone is the recipient of the Pew Charitable Trusts Scholar Award and the Leukemia and Lymphoma Society Scholar Award.
Other Ohio State researchers involved in this study were Hui Wanga, Matt Karikomi, Shan Naidu, Ravi Rajmohan, Enrico Caserta, Hui-Zi Chena, Maysoon Rawahneh, Julie Moffitt, Julie A. Stephens, Soledad A. Fernandez, Michael Weinstein, Danxin Wang, Wolfgang Sadee, Krista La Perle, Paul Stromberg and Thomas J. Rosol.
The Ohio State University Comprehensive Cancer Center- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (http://cancer.osu.edu) is one of only 40 Comprehensive Cancer Centers in the United States designated by the National Cancer Institute. Ranked by U.S. News & World Report among the top 20 cancer hospitals in the nation, The James is the 180-bed adult patient-care component of the cancer program at The Ohio State University. The OSUCCC-James is one of only seven funded programs in the country approved by the NCI to conduct both Phase I and Phase II clinical trials.
Click here for a high quality JPEG of Dr. Leone
Click here for a high quality JPEG of Dr. Ostrowski
Darrell E. Ward
Medical Center Communications